News Sentiment

MGNX sentiment intelligence

MacroGenics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.33 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-8.1% over one week, +9.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

[144] MACROGENICS INC SEC Filing

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -8.1% Price reacting lower
Trend fit Trend active 9.3% over four weeks
Fair value -8.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 10
Stock Titan 6
Investing.com 4
simplywall.st 4
Seeking Alpha 3
www.marketscreener.com 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 15
Regulatory and legal 7
Deals and strategy 6
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Stock Titan Direct company coverage

[144] MACROGENICS INC SEC Filing

This article details a Form 144 SEC filing by MacroGenics Inc. for a proposed sale of securities under Rule 144. The filing indicates the sale of 17,000 common shares with an aggregate market value of $75,529, acquired on July 13, 2026, through a stock plan activity. The projecte

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 01:40
Source
Stock Titan
MarketBeat Direct company coverage

MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026

MacroGenics (MGNX) saw a significant 38.33% increase in short interest as of June 30, 2026, with 6.63 million shares sold short, representing 12.07% of its public float. The short interest ratio stands at 3.5 days to cover. This data suggests growing bearish sentiment among inves

Tone
Negative 35/100
Event
Market update
Published
10 Jul 2026 07:41
Source
MarketBeat
www.marketscreener.com Direct company coverage

Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026

Macrogenics, Inc. announced that Karen Ferrante, M.D. will resign from its board of directors, effective September 1, 2026. Dr. Ferrante's decision is for personal reasons and does not stem from any disagreement with the company's operations, policies, or practices. The announcem

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:11
Source
www.marketscreener.com
Minichart Direct company coverage

MacroGenics, Inc. 8-K SEC Filing July 2026: Company Details, Stock Info, and Key Regulatory Disclosures

MacroGenics, Inc. (NASDAQ: MGNX) announced the resignation of Dr. Karen Ferrante from its board of directors, effective September 1, 2026, due to personal reasons. The company emphasized that her departure was amicable and not related to any disagreements, reassuring investors. T

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 01:10
Source
Minichart
TradingView Direct company coverage

Karen Ferrante to Resign from MacroGenics' Board Effective Sept 1, 2026

MacroGenics (MGNX) announced that Karen Ferrante, M.D., will resign from its board of directors, effective September 1, 2026. The resignation is due to personal reasons and is not a result of any disagreement with the company. No information was disclosed regarding a replacement

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026

MacroGenics, Inc. announced that board member Karen Ferrante, M.D. will resign from its board of directors effective September 1, 2026, due to personal reasons. She notified the board on July 1, 2026, and the company confirmed that her decision is not due to any disagreements reg

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:10
Source
Stock Titan
AD HOC NEWS Direct company coverage

MacroGenics Inc highlights its oncology pipeline as investors track future catalysts

MacroGenics Inc, a US-based biotechnology company, is actively advancing its antibody-based cancer therapies, providing investors with exposure to the specialized immuno-oncology segment. The company focuses on developing monoclonal antibody and antibody-based product candidates

Tone
Positive 69/100
Event
Market update
Published
08 Jul 2026 13:10
Source
AD HOC NEWS
Stock Titan Direct company coverage

MacroGenics (NASDAQ: MGNX) nets $110.7M and gain in CDMO sale

MacroGenics, Inc. has completed the sale of its GMP drug substance manufacturing and CDMO operations to Bora Pharmaceuticals and Bora Biologics for $122.5 million. This divestiture resulted in net cash proceeds of $110.7 million and is expected to transform the company's pro form

Tone
Positive 71/100
Event
Balance sheet
Published
07 Jul 2026 20:42
Source
Stock Titan
Contract Pharma Direct company coverage

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Mfg. Ops

Bora Pharmaceuticals has completed its acquisition of MacroGenics' GMP manufacturing operations, including its Rockville, MD biologics drug substance facility, for $122.5 million. This acquisition establishes Bora Biologics with a 20,000-liter U.S. biologics drug substance manufa

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 18:42
Source
Contract Pharma
The Globe and Mail Direct company coverage

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics, a clinical-stage biopharmaceutical company, has completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. As part of the deal, Bora Pharmaceuticals has acquired MacroGenics' manufacturing site in Rockville, Mary

Tone
Positive 72/100
Event
Deals and strategy
Published
03 Jul 2026 04:39
Source
The Globe and Mail
Media OutReach Newswire Direct company coverage

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

Bora Pharmaceuticals has completed its acquisition of MacroGenics' GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland, and a warehousing center, for $122.5 million. This acquisition establishes a 20,000-liter US biologics drug subst

Tone
Positive 72/100
Event
Deals and strategy
Published
03 Jul 2026 04:09
Source
Media OutReach Newswire
Investing.com Direct company coverage

MacroGenics completes sale of manufacturing operations to Bora

MacroGenics Inc. has completed the sale of its drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. for $122.5 million. This transaction includes the transfer of MacroGenics' Rockville and Frederick facilities, along with approximately 140 employees. The deal

Tone
Positive 75/100
Event
Deals and strategy
Published
02 Jul 2026 13:39
Source
Investing.com
Stock Titan Direct company coverage

MacroGenics sells its drug-making operations to Bora for $122.5M

MacroGenics (NASDAQ: MGNX) completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. The deal includes the transfer of MacroGenics' manufacturing site in Rockville, Maryland, and its Frederick warehouse, along with approxima

Tone
Positive 67/100
Event
Deals and strategy
Published
02 Jul 2026 13:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark

MacroGenics, Inc. (NasdaqGS: MGNX) has been added to the Russell 2500 Growth Benchmark as of June 29, 2026. This inclusion reflects the company's growth characteristics and follows several other Russell index additions on the same date, including the Russell Small Cap Comp Growth

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 19:11
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of MacroGenics, Inc. – NASDAQ:MGNX

This article focuses on the enterprise value to revenue forward metric for MacroGenics, Inc. (NASDAQ: MGNX). It indicates that the information is provided by TradingView's financial data section. The content primarily serves as a placeholder or a brief mention within a larger fin

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 01:12
Source
TradingView
TradingView Direct company coverage

Price to sales forward of MacroGenics, Inc. – NASDAQ:MGNX

This article briefly mentions the price to sales forward metric for MacroGenics, Inc. (NASDAQ: MGNX). It appears to be a stub or a section focused solely on this financial data point within a larger platform like TradingView, lacking substantial textual content or analysis. The m

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of MacroGenics, Inc. – NASDAQ:MGNX

This article displays financial information for MacroGenics, Inc. (NASDAQ: MGNX) focusing on its price to earnings forward ratio. The content is primarily a data placeholder from TradingView, indicating where specific financial metrics would be presented.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 15:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of MacroGenics, Inc. – BOATS:MGNX

This article focuses on the enterprise value to revenue forward for MacroGenics, Inc. (MGNX). It provides financial data and an overview of the company's performance within the Health Technology and Pharmaceuticals sector. The content, available through TradingView and supported

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of MacroGenics, Inc. – BOATS:MGNX

This article provides financial data for MacroGenics, Inc. (MGNX), specifically focusing on its "Price to book forward" metric. The content highlights the stock's performance within the Health Technology and Pharmaceuticals sector, presenting an overview from the Blue Ocean Alter

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 16:39
Source
TradingView
TradingView Direct company coverage

MGNX Forecast — Price Target — Prediction for 2027

This article provides a forecast for MacroGenics, Inc. (MGNX) stock, including analyst price targets, past performance, and future estimates. It highlights that analysts have a max price estimate of $9.00 and a min estimate of $4.00, with the stock having seen significant growth

Tone
Positive 60/100
Event
Analyst action
Published
26 Jun 2026 08:40
Source
TradingView
TradingView Direct company coverage

MacroGenics, Inc. Actuals & Estimates (NASDAQ:MGNX)

This article provides an overview of MacroGenics, Inc. (NASDAQ:MGNX) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, financial estimates, and key financial metrics like earnings, revenue, and EBITDA. The report

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

M55 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for MacroGenics, Inc. (M55) stock, based on analyst opinions, with a max estimate of 7.29 CHF and a min estimate of 3.24 CHF. It also includes key financial data such as market capitalization, recent earnings, revenue, net income,

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:39
Source
TradingView
Pulse 2.0 Direct company coverage

MacroGenics To Receive $24.5 Million Milestone From Sanofi For TZIELD Approval

MacroGenics will receive a $24.5 million regulatory milestone payment from Sanofi after the FDA granted accelerated approval for TZIELD. This approval expands TZIELD's use for delaying the decline in endogenous insulin production in children aged eight to 17 years with recently d

Tone
Neutral 50/100
Event
Regulatory and legal
Published
24 Jun 2026 02:40
Source
Pulse 2.0